Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Annual incidence of Multiple Sclerosis in a large Health Care System in the US from 2014 to 2020
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-003
Previous studies measuring incidence of multiple sclerosis (MS) in the US have been limited by single payer cohorts and short observation periods. Measuring incidence in diverse cohort using established case definition and sufficient observation time has better potential to detect cases and temporal changes. Such estimation of MS incidence is valuable for the assessment of resource needs and healthcare burden.
Estimate annual incidence of MS during 2014-2020 in a large healthcare system in the US.
This retrospective observational study estimated the annual incidence rate of MS from 2014 to 2020. The population was derived from a linked dataset combining the Colorado All-payers Claims Database with electronic health records from University of Colorado Health system, capturing 18.1% of the Colorado population. MS cases were initially identified using the Multiple Sclerosis Prevalence Workgroup Algorithm. The numerator included individuals in the MS case cohort who were continuously enrolled in insurance coverage for 24 months prior to the first observable MS event (index date). For each calendar year, the denominator was total person-time of the population at risk. Incidence was age-adjusted using the 2010 Census to calculate nationally representative estimates for comparability with other US studies.
A total of 1118 incident MS cases were identified from 5,080,555 total person-years of observation. The overall incidence rate of MS from 2014 to 2020 was 21.57 per 100,000 person-years (95% CI=20.29, 22.85). The incidence of MS was greatest in 2015 (26.49, 95% CI=22.74, 30.25) and the lowest in 2020 (17.48, 95% CI=14.27, 20.69). The annual percentage change of incidence was -5.07% (p=0.041).
Incidence in the current all-payer cohort was higher compared to older US estimates in single payer settings. Decreasing trend of MS incidence is a trend also observed by a contemporary study in Canada. Work is in progress to describe the demography of the incident cases.
Authors/Disclosures
Sue Hyun Kwon
PRESENTER
Ms. Kwon has nothing to disclose.
Aaron M. Carlson, MD (University of Colorado, School of Medicine, Department of Neurology) Dr. Carlson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Carlson has received research support from Horizon Therapeutics. Dr. Carlson has a non-compensated relationship as a Health Service Subcommittee Member with American Academy of Neurology that is relevant to AAN interests or activities.
Robert Valuck No disclosure on file
Kelly Anderson (University of Colorado) No disclosure on file
Kavita Nair, PhD, FAAN (University of Colorado) Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Healthcare. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS.
Heather Anderson No disclosure on file